Human study to evaluate the efficacy and safety of NS2309 on respiratory health

Gachon University Gil Medical Center0 个研究点目标入组 100 人开始时间: 待定最近更新: 2024年1月22日

试验速览

暂无简介。

•1) Subject who agrees to participate in the study and signs the informed consent form
•2) 40–74 years old
•3) persistent respiratory symptoms including cough and sputum more than 3 months

•1) abnormal FEV1/FVC
•2) respiratory diseases including tuberculous-destroyed lung, bronchiectasis, acute bronchitis, chronic bronchitis, asthma, COPD, lung cancer, pneumonia, tuberculosis, acute upper respiratory infections, diabetes, cardiovascular diseases, GERD
•3) taking pills or extracts of quince or deodeok within recent 2 weeks persistently
•4) taking antioxidants or anti-inflammatory drugs or dietary supplements within recent 6 weeks
•5) serum creatinine = 2 mg/dL or ESRD
•6) total bilirubin = 2 mg/dL, AST or ALT = 1.5 x normal value
•7) uncontrolled psychologic disease or alcoholics
•9) BMI = 35kg/m2
•10) history of hypersensitivity for testing substance or severe food allergy
•11) involving other clinical trials within 1month
•12) pregnant or lactating, or planning to become pregnant
•13) the investigator's decision

发起方